Geng et al. in their 2022 review explored the links between gut microbiota and obesity-related diseases, such as diabetes and cardiovascular disease, highlighting the therapeutic potential of prebiotics and probiotics in reducing systemic inflammation and improving insulin sensitivity. The gene discussed is INS; the disease is cardiovascular disorder.